Use of erythropoietin in the management of the haemolytic uraemic syndrome induced by mitomycin C/tamoxifen.
O'Brien
M E
ME
Casey
S
S
Treleaven
J
J
Powles
T J
TJ
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000628:therapy*; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects; D013629:Tamoxifen / Q000009:adverse effects
D013629:Tamoxifen; D004921:Erythropoietin; D016685:Mitomycin